Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
475.4 USD | +0.36% |
|
-1.53% | +16.53% |
17/06 | Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 | MT |
14/06 | Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.53% | 12TCr | |
+19.25% | 11TCr | |
+2.62% | 2.27TCr | |
-16.41% | 2.13TCr | |
-39.57% | 1.69TCr | |
-13.99% | 1.67TCr | |
-16.31% | 1.66TCr | |
+3.46% | 1.36TCr | |
+22.17% | 1.1TCr | |
+109.13% | 1.04TCr |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials